- Home
- ECVT vs GLUE Comparison
ECVT vs GLUE Comparison
Compare ECVT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECVT | GLUE |
|---|---|---|
| Founded | 1935 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECVT | GLUE |
|---|---|---|
| Price | $10.21 | $13.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $14.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.2M | 948.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $723,515,000.00 | $123,672,000.00 |
| Revenue This Year | $29.07 | N/A |
| Revenue Next Year | $6.71 | $2.45 |
| P/E Ratio | $91.82 | ★ $72.42 |
| Revenue Growth | 2.70 | ★ 63.54 |
| 52 Week Low | $7.41 | $6.07 |
| 52 Week High | $15.09 | $25.77 |
Technical Indicators
Market Signals| Indicator | ECVT | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 37.81 |
| Support Level | $9.80 | N/A |
| Resistance Level | $10.73 | $16.66 |
| Average True Range (ATR) | 0.29 | 0.78 |
| MACD | 0.07 | 0.19 |
| Stochastic Oscillator | 30.77 | 38.90 |
Price Performance
Historical ComparisonAbout ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).